RxDoctor Payments Data

Jason Wolff, MD

Interventional Pain Medicine · Maple Grove, MNNPI 1376759845

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Medtronic at 53.1% of the total. Reporting peaked in 2022 at $2,825 and has fallen 85.5% since, to $408 in 2025.

$8,604in general payments, 2019–2025

Across 148 payments — averaging $58.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Nevro Corp.$992
  • Relievant Medsystems, Inc.$830
  • Abbott$629
  • Si-bone, Inc.$413
  • Boston Scientific$412
  • plus $758 from 14 others
$73,984in research payments, 2019–2025

Across 7 payments — averaging $10,569 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$74K

What the payments were for

  • Speaking & faculty fees$3,60042%
  • Travel & lodging$5216%
  • Food & beverage$4,47152%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,604 in reported general payments places this provider in the 80th percentile of 26 interventional pain medicine providers in Minnesota.

See all interventional pain medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$129,216
Medicare patients
351
Services billed
2,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin111$1,581
Tizanidine Hcl56$806
Methocarbamol21$270
Duloxetine Hcl21$263
Baclofen18$235
Cyclobenzaprine Hcl29$221
Methylprednisolone29$179
Hydroxyzine Pamoate16$149
Cephalexin14$128
Amitriptyline Hcl12$49
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$33

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Maple Grove

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →